Rifamycin congeners kanglemycins are active against rifampicin-resistant bacteria via a distinct mechanism

Abstract excerpt

Abstract Rifamycin antibiotics (Rifs) target bacterial RNA polymerases (RNAPs) and are widely used to treat infections including tuberculosis. The utility of these compounds is threatened by the increasing incidence of resistance (Rif R ). As resistance mechanisms found in clinical settings may also occur in natural environments, here we postulated that bacteria could have evolved to produce rifamycin congeners...

Topics

Share this publication in a Topic to start or enrich a Post.

• Share to Antibiotic Resistance in Bacteria
• Share to Bacteriophages and microbial interactions
• Share to Tuberculosis Research and Epidemiology